Trial: 201804011

A Phase 2 Trial of the MEK inhibitor selumetinib (AZD6244 hydrogen sulfate) in combination with the mTOR inhibitor sirolimus for patients with unresectable or metastatic malignant peripheral nerve sheath tumors

Phase

II

Principal Investigator

Van Tine, Brian

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov